The World Health Organization is revamping its Ebola vaccination strategy in Congo as the outbreak continues to outrun vaccination efforts and supply of Merck's Ebola vaccine dwindle, according to a WHO news release.
Four things to know:
1. The strategy was introduced May 7 by the WHO Strategic Advisory Group of Experts.
2. The WHO said that 111,000 people have been vaccinated, but the number of cases continues to rise due to violence in the area.
3. Because supplies of the approved Merck vaccine are running low, the strategy includes introducing Johnson & Johnson's experimental Ebola vaccine.
4. The WHO advisory group recommended adjusting the current dosage of Merck's Ebola vaccine to "ensure vaccine continues to be available and offered to individuals at greatest risk of Ebola."
Read the full news release here.
More articles about supply chain:
Philadelphia hospital investigating theft of $25K in endoscopes
The 1st pediatric dengue vaccine, a wearable arrhythmia monitor & more: 5 recent FDA approvals
FDA won't ban breast implants linked to cancer for now